Gilead to license generic lenacapavir for HIV prophylaxis in 120 lower income countries
Ireland based pharmaceutical company Gilead Sciences has said it will grant licences to six generic manufacturers to produce low cost lenacapavir, which has shown unprecedented efficacy at preventing HIV infection, in 120 countries for a fraction of its …